The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for managing obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a greater substantial decrease in body weight and improve metabolic health, particular